Proteins and Peptides
2 January 2014
NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome25 December 2013
FDA Approves TRETTEN® for the Treatment of Congenital Factor XIII A-Subunit Deficiency23 December 2013
European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin21 December 2013
Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product20 December 2013
Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes20 December 2013
Novo Nordisk files for regulatory approval of liraglutide19 December 2013
Blaze Bioscience Announces Initiation of First-in-Human Phase 1 Clinical Study of BLZ-10019 December 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors17 December 2013
Finox Biotech Announces First Patients Enrolled in Pivotal US Phase III (FIN3002) study for rFSH16 December 2013
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment11 December 2013
Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan11 December 2013
Kamada Announces Completion of Pivotal Phase II/III Clinical Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency10 December 2013
Baxter Submits Application for FDA Approval of OBI-1 for Patients with Acquired Hemophilia A10 December 2013
CSL Behring Study Shows Kcentra® Superior to Plasma for Warfarin Reversal in Patients Requiring an Urgent Surgical Procedure10 December 2013
Baxter Files for Pediatric Indication of RIXUBIS (Coagulation Factor IX (Recombinant)] Treatment for Hemophilia B in the United States10 December 2013
New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ and ELOCTATE™ Across Multiple Hemophilia Populations7 December 2013
Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX® for the Treatment of Peyronie’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports